What are the possible side effects of nirogacestat?

Nirogacestat (nirogacestat), as a γ-secretase inhibitor, has shown significant efficacy in the treatment of progressive desmoid tumors, but its targeting mechanism may also cause a series of specific side effects that need to be monitored and managed during treatment. According to overseas research and medication observations, the most common side effects include diarrhea, fatigue, nausea, stomatitis, decreased appetite, and electrolyte disorders, such as hypophosphatemia or hyponatremia. These adverse reactions are mostly related to its interference with the Notch signaling pathway, affecting intestinal epithelium and other normal cell functions.

In addition, female patients may experience suppression of ovarian function, manifested by irregular menstruation or amenorrhea, suggesting that attention should also be paid to its impact on the reproductive axis, especially in women during the childbearing period, where evaluation and family planning guidance should be strengthened. Some patients may also experience musculoskeletal discomfort, such as joint pain or muscle soreness during long-term use, which may be related to the drug's effect on bone metabolism or tissue repair mechanisms. Although rare, some patients may develop mild liver function abnormalities or rash, suggesting that regular liver function monitoring is necessary during treatment.

It is worth emphasizing that these side effects are mild to moderate in most patients and can be alleviated through dose reduction, intermittent medication, or symptomatic treatment. However, for those with severe or persistent symptoms, the treatment plan should be adjusted in a timely manner. To improve patient compliance and safety, it is clinically recommended to conduct a comprehensive assessment before medication, including baseline testing of liver and kidney function, electrolyte levels, and reproductive system status.

Overall, the safety profile of nilogacestat is within an acceptable range among targeted therapies, and its side effect profile is milder than that of chemotherapy. However, individualized evaluation and dynamic follow-up are still required to maximize the balance between efficacy and safety.

Reference materials:https://www.drugs.com/mtm/nirogacestat.html